Arcus Biosciences Stock Analysis

Arcus Stock Analysis Notes

About 83.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.95. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Arcus Biosciences recorded a loss per share of 3.14. The entity had not issued any dividends in recent years. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 366 people. To find out more about Arcus Biosciences contact Terry Rosen at 510 694 6200 or learn more at https://www.arcusbio.com.

Arcus Biosciences Investment Alerts

Arcus Biosciences Upcoming and Recent Events

Arcus Largest EPS Surprises

View All Earnings Estimates

Arcus Biosciences Environmental, Social, and Governance (ESG) Scores

Arcus Stock Institutional Investors

Note, although Arcus Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Arcus Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 946.22 M.

Arcus Profitablity

The company has Profit Margin (PM) of (1.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.96) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.96.

Management Efficiency

Arcus Biosciences has return on total asset (ROA) of (0.1726) % which means that it has lost $0.1726 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5977) %, meaning that it created substantial loss on money invested by shareholders. Arcus Biosciences' management efficiency ratios could be used to measure how well Arcus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.26 in 2025. Return On Capital Employed is likely to drop to -0.37 in 2025. At this time, Arcus Biosciences' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 204.6 M in 2025, whereas Other Assets are likely to drop slightly above 8.5 M in 2025.

Technical Drivers

As of the 23rd of March, Arcus Biosciences shows the mean deviation of 2.55, and Risk Adjusted Performance of (0.19). In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Arcus Biosciences, as well as the relationship between them. Please confirm Arcus Biosciences mean deviation and maximum drawdown to decide if Arcus Biosciences is priced correctly, providing market reflects its regular price of 8.94 per share. Given that Arcus Biosciences has information ratio of (0.21), we suggest you to validate Arcus Biosciences's prevailing market performance to make sure the company can sustain itself at a future point.

Arcus Biosciences Price Movement Analysis

Arcus Biosciences Insider Trading Activities

Arcus Biosciences Outstanding Bonds

Arcus Biosciences Predictive Daily Indicators

Arcus Biosciences Corporate Filings

Arcus Biosciences Forecast Models

Arcus Biosciences' time-series forecasting models are one of many Arcus Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arcus Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Arcus Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Arcus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Arcus Biosciences. By using and applying Arcus Stock analysis, traders can create a robust methodology for identifying Arcus entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Arcus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Arcus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Arcus Biosciences stock analysis indicators help investors evaluate how Arcus Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Arcus Biosciences shares will generate the highest return on investment. By understating and applying Arcus Biosciences stock analysis, traders can identify Arcus Biosciences position entry and exit signals to maximize returns.

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.